First Choice Neurology is pleased to announce that Icobrain®, an advanced artificial intelligence software for quantitative brain MRI analysis, is now available at our MRI Center in Miami. The technology gives radiologists and neurologists additional information to help evaluate and monitor multiple sclerosis, dementia, Alzheimer’s disease, and amyloid-related imaging abnormalities, also known as ARIA.
A brain MRI is an important part of neurological care, but some changes are subtle and may be difficult to measure consistently by visual review alone. Icobrain analyzes MRI images, measures specific brain structures and abnormalities, and helps compare scans from different points in time. These measurements can support earlier recognition of meaningful changes and more informed information about diagnosis, treatment response, and next steps.
How Artificial Intelligence Supports Brain MRI Analysis
A standard MRI produces detailed pictures of the brain. Icobrain adds a quantitative layer to that imaging. After an MRI is completed, the software processes the scan in the background. It then generates a report with measurements and color-coded images for the radiologist to interpret and the neurologist to review. For the patient, the MRI experience generally does not change because of the software.
The goal is not to replace the expertise of a radiologist or neurologist. Instead, Icobrain functions as an assistive tool. It can help clinicians identify, measure, and compare findings that may be difficult to track by eye, especially when small changes occur gradually. The final interpretation still depends on a neurologist. The neurologist considers the imaging together with symptoms, examination findings, medical history, laboratory testing, and other relevant information.
Why Comparing Brain MRIs Over Time Matters
Many neurological conditions develop or change over months and years. A single MRI provides a snapshot, but a series of MRIs can show whether lesions have appeared, brain tissue volume has changed, or treatment-related findings have developed. This is called longitudinal monitoring.
A longitudinal MRI review can be time-consuming, and differences in positioning, scanning technique, or anatomy can make direct comparisons challenging. Icobrain is designed to support a more standardized comparison by calculating objective measurements. Added information may help neurologists determine whether a condition appears stable, whether it is progressing, or whether a treatment plan should be reassessed.
Icobrain MS for Multiple Sclerosis Monitoring
Multiple sclerosis, or MS, is a chronic immune-mediated disease of the central nervous system. It can damage myelin, the protective covering around nerve fibers. This may lead to lesions in the brain and spinal cord. MRI is widely used to help diagnose MS and monitor disease activity.
Icobrain MS supports the detection and follow-up of MS-related changes. It can quantify FLAIR lesions, T1 lesions, and brain volume, then show how those measurements change between scans. This may give a neurologist and/or MS specialist a clearer view of inflammatory disease activity and possible tissue loss over time.
Why does that matter? A person may feel stable even while an MRI shows new or enlarging lesions. In other cases, symptoms may change without clear new MRI activity. Imaging is only one part of the picture, but more consistent measurements can help the neurologist evaluate whether a disease-modifying therapy appears to be controlling MS or whether additional discussion is warranted.
Icometrix reported that Icobrain-assisted review increased the detection of MS disease activity by 150% in one study and, in a separate health-economic modeling study, was associated with 2.5-times faster identification of treatment failure.
Icobrain DM for Dementia and Alzheimer’s Disease
Alzheimer’s disease and other forms of dementia often progress gradually. Changes in memory, thinking, language, or daily functioning may be difficult to measure over a short period. Symptoms alone may not fully reflect the changes occurring in the brain.
Icobrain DM helps clinicians evaluate patterns of brain atrophy, meaning loss of brain volume. It measures structures that can be important in dementia assessment, including the hippocampi and cortical lobes, and compares the results with data from a healthy reference population. When more than one MRI is available, the software can also help show how brain volume has changed over time.
These measurements may support the early identification of imaging patterns associated with cognitive disorders and help with differential diagnosis, which is the process of distinguishing among possible causes. They may also help a neurologist assess whether imaging findings appear stable or progressive. Furthermore, they can guide follow-up planning and explain results more clearly to patients and caregivers.
Icobrain does not diagnose Alzheimer’s disease by itself. A thorough evaluation may also include a medical history, neurological examination, cognitive testing, laboratory studies, and, when appropriate, biomarker testing. The neurologist determines which tests are suitable for each patient.
Icobrain ARIA and the Safety of Anti-Amyloid Treatment
Newer anti-amyloid therapies, including lecanemab (Leqembi®) and donanemab (Kisunla™), may be considered for certain people with early Alzheimer’s disease who meet specific clinical and biomarker criteria. These treatments require careful evaluation and ongoing MRI monitoring because they can be associated with amyloid-related imaging abnormalities.
ARIA can include swelling or fluid accumulation called ARIA-E, as well as small areas of bleeding or iron deposits called ARIA-H. Some people with ARIA have no symptoms, while others may experience headache, confusion, dizziness, vision changes, nausea, or seizures. Because ARIA can affect treatment decisions, patients need a baseline MRI before therapy. In addition, they need follow-up scans according to the medication’s prescribing information and the treating neurologist’s judgment.
Icobrain ARIA assists radiologists by detecting, measuring, and grading findings associated with ARIA-E and ARIA-H. The software can identify features such as edema, sulcal effusion, microhemorrhages, and superficial siderosis. A structured quantitative report may support more consistent evaluation and help the neurologist make informed decisions about continuing, pausing, or adjusting therapy.
In November 2024, the U.S. Food and Drug Administration granted 510(k) clearance to Icobrain ARIA for detecting, measuring, and grading ARIA. It was described at clearance as the first AI software specifically cleared for this purpose.
What Does Icobrain Mean for Patients
For patients, the main benefit is additional objective information. Instead of relying only on a visual impression, your neurologist can review measurable changes in lesions, brain volume, or ARIA findings. This can make follow-up discussions more specific and may help clinicians recognize a meaningful trend sooner.
Depending on the patient and the reason for imaging, Icobrain may help your neurologist:
• Compare current and prior brain MRIs more consistently
• Measure MS lesion burden and brain volume changes
• Evaluate patterns of brain atrophy associated with cognitive disorders
• Detect and grade ARIA during anti-amyloid treatment monitoring
• Assess disease stability or progression alongside symptoms and examination findings
• Support timely, individualized treatment discussions
Not every patient needs quantitative MRI analysis, and no AI result should be interpreted in isolation. Your neurologist will decide whether Icobrain is appropriate based on your diagnosis, symptoms, treatment, previous imaging, and overall clinical needs.
Frequently Asked Questions About Icobrain
Does Icobrain diagnose multiple sclerosis or Alzheimer’s disease?
No. Icobrain provides measurements and image-based information that assist radiologists and neurologists. A diagnosis requires a complete clinical evaluation and may involve several different tests.
Will my MRI feel different?
Usually, no. Icobrain analyzes the MRI images after they are acquired. Your care team will explain the MRI procedure, whether contrast is needed, and any preparation instructions.
Why is brain volume important in MS and dementia?
Changes in brain volume can provide information about tissue loss over time. However, volume measurements must be interpreted carefully because aging, other medical conditions, scan quality, and additional factors can influence results.
What is ARIA on an MRI?
ARIA refers to MRI findings that can occur in people receiving amyloid-targeting Alzheimer’s therapies. ARIA-E involves swelling or fluid-related changes, while ARIA-H involves microhemorrhages or superficial siderosis. Monitoring helps the treatment team protect patient safety and make dosing decisions.
Where is Icobrain available in Miami?
Icobrain is now available through the First Choice Neurology MRI Center in Miami, located at 9085 SW 87 Avenue, Suite 201. Patients should speak with their neurologist to determine whether quantitative brain MRI analysis is appropriate and how to schedule the recommended imaging.
Advanced Brain Imaging at First Choice Neurology
The addition of Icobrain reflects First Choice Neurology’s commitment to using clinically validated technology to support neurological diagnosis, monitoring, and treatment planning. By combining advanced MRI analysis with the experience of radiologists and neurologists, we can give patients and families clearer information and more personalized guidance.
To learn more about Icobrain, MS care, memory evaluations, Alzheimer’s treatment monitoring, or MRI services in Miami, speak with your First Choice Neurology provider.
Medical note: This blog is for educational purposes and is not a substitute for individualized medical advice, diagnosis, or treatment. Availability and suitability of testing and therapy vary by patient.
References: